None
Quote | Allogene Therapeutics Inc. (NASDAQ:ALLO)
Last: | $2.855 |
---|---|
Change Percent: | 1.64% |
Open: | $2.99 |
Close: | $2.855 |
High: | $2.99 |
Low: | $2.84 |
Volume: | 2,772,062 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Allogene Therapeutics Inc. (NASDAQ:ALLO)
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participat...
2024-04-05 11:30:00 ET Summary There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered. We lead off with some of the most discussed articles from last month, with a few that generated over 100 com...
Message Board Posts | Allogene Therapeutics Inc. (NASDAQ:ALLO)
Subject | By | Source | When |
---|---|---|---|
An oral presentation at AACR next month https://www.abstractsonline.com/pp8/#!/1 | jondoeuk | investorshub | 03/22/2023 9:14:22 PM |
A proprietary approach to control rejection https://www.globenewswire.com/news-r | jondoeuk | investorshub | 03/22/2023 9:12:05 PM |
R&D showcase PR https://www.globenewswire.com/news-release/2022/11/29/2564467/0/ | jondoeuk | investorshub | 03/22/2023 9:09:42 PM |
ASGCT PR https://www.globenewswire.com/news-release/2022/05/19/2446950/0/en/Allo | jondoeuk | investorshub | 05/19/2022 5:36:05 PM |
New preclinical data https://aacrjournals.org/cancerrescommun/article/2/3/158/68 | jondoeuk | investorshub | 03/24/2022 3:08:02 AM |
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology compan...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participat...
Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL) : Start-Up Activities Underway; Enrollment to Begin Mid-2024 Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Dat...